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Research with humans and animals has been developed over the past few years 
to identify receptors involved in Alzheimer’s disease, aiming at a better understand-
ing of the mechanisms and pathophysiological aspects associated with the disease. 
Such receptors, whether or not directly associated with current AD therapy, are 
relevant since their blockage or activation might result in improving or worsening 
the clinical scenario of the disease. In other words, such receptors might be involved 
in the AD prognosis. This chapter discusses some relevant points about the recep-
tors involved with AD.
Keywords: neuroprotection, Alzheimer disease, receptors, beta-amyloid peptides, 
central nervous system, agonists, antagonists
1. Introduction
Alzheimer’s disease (AD) is the most recurring chronic and incurable neurode-
generative disorder. The main neuropathological findings on AD are beta-amyloid 
protein plaque (APP) deposition, an accumulation of hyperphosphorylated 
neurofibrillary tangles, inflammation, neurotransmitter signaling dysregulation, 
brain atrophy, and neuronal changes. AD affects the central nervous system (CNS) 
and results in an impaired emotional state, loss of synapses, neuronal death, and 
progressive cognitive decline. Some risk factors such as advanced age, genetic fac-
tors, and head trauma (among others) are involved in AD progression. Alzheimer’s 
disease is responsible for marked morbidity and mortality due to the difficulty in 
treatment and irreversible damage. However, there is condition stabilization in 
some cases, and the individual can postpone their life expectancy for years [1].
2. Alzheimer’s disease-associated receptors
2.1 Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptors (nAChR) are involved with neuroprotective 
effects in AD. Furthermore, nAChR agonists and antagonists have been shown to 
have positive effects on memory. Cotinine and methyl cyclonite are examples of 
nAChR ligands associated with brain protection when in vitro and in vivo tests 
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have been performed. In addition, nAChR and the muscarinic acetylcholine recep-
tor family (mAChR) are acetylcholine targets in the brain. The nAChR family is 
affected in AD because beta-amyloid peptides (Aβ) can interact with these recep-
tors [1]. Acetylcholine (Ach) plays a crucial role in CNS. Choline acetyltransferase 
enzyme is responsible for ACh synthesis from acetyl-CoA and choline in the 
cytoplasm. The acetylcholine vesicular transporter absorbs the neurotransmitter 
in synaptic vesicles. After depolarization, ACh undergoes exocytosis in reaching 
the synaptic cleft, where it can bind with its receptors. The ACh in the synaptic 
cleft is readily hydrolyzed by the acetylcholinesterase enzyme, forming acetate and 
choline, which is recycled at the presynaptic nerve terminal by the high-affinity 
choline transporter. Cholinergic neurons located in the basal forebrain, including 
the neurons which form Meynert’s basal nucleus, are severely affected in AD. The 
loss of cholinergic neurons contributes to memory and attention deficits. Therefore, 
drugs acting on the cholinergic system represent a promising option for treating 
AD patients [2]. The conventional therapeutic prescription for AD consists of three 
acetylcholinesterase inhibitors and one NMDA receptor antagonist. Researchers 
around the world are developing new nAChR agonists to develop drugs with lower 
risks and adverse effects [3].
2.2 Estrogen receptor
Another important target in AD is the estrogen receptor (ER), which may 
represent a promising therapeutic approach since its activation through agonists 
prolongs survival, improves spatial recognition memory, and decreases the amy-
loid pathology progression in animal models of AD. On the other hand, estrogen 
receptor genetic polymorphisms have been associated with cognitive impairment, 
accelerated brain aging, and increased risk of AD, predominantly in women. A 
methylation promoter in estrogen receptor α is also related to impaired cognitive 
function and quality of life in AD patients by inhibiting ERα mRNA expression and 
transcription [4]. Estrogen can increase neural plasticity, cognitive functions, and 
the brain’s regenerative potential. The beneficial effects of estrogen on neural plas-
ticity occur at three levels: cellular, morphological, and synaptic function. Studies 
have shown that estradiol can increase neurogenesis in several brain regions, such as 
the hippocampal gyrus. These estrogen-induced hippocampal neurons contribute 
to learning and memory. Estradiol can also rapidly increase the number of dendritic 
spines in the hippocampus, amygdala, and hypothalamus and thus improve the 
performance in a hippocampal-dependent memory task. Moreover, estradiol is an 
effective enhancer of synaptic transmission in the hippocampal system. Estradiol 
plays an important role in promoting neurogenesis and neuronal plasticity to 
maintain healthy cognitive function and protect against women’s cognitive decline 
during aging [5]. Therefore, estrogen with selective effects on ERα or G protein-
coupled estrogen receptors (GPER1 or GqMER) can be used to influence the inflam-
mation process resolution, with positive effects on AD progression [6].
2.3 Ryanodine receptor
Ryanodine receptors (RyR) are an ion channel family responsible for calcium 
release from intracellular reserves during muscle contraction. Calcium homeostasis 
is known to be related to cognition; thus, RyR may be associated with AD, especially 
RyR 3, which is found in various nervous system areas. In addition, RyR 1 and RyR 
2 are also found in the brain, although they are not predominantly present in the 
nervous system. Ryanodine receptors can be regulated by several proteins and ions, 
as well as redox modifications. Antioxidants importantly prevent cognitive decline, 
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long-term depolarization, and memory loss by inhibiting RyR sensitization [7]. 
Calcium-dependent signaling pathways are related to AD pathogenesis. A phar-
macological approach (using a RyR stabilizing drug) or gene therapy of calcium 
leakage (mediated by RyR2) improved synaptic plasticity, and behavioral and 
cognitive functions and reduced Aβ loading. Genetically, altered mice (congenital 
leaking of RyR2) exhibited premature and severe defects in synaptic plasticity, and 
behavioral and cognitive function. These data provide an underlying mechanism 
for RyR2 channels, which can be considered as possible therapeutic targets in AD 
[8]. Additionally, calcium accumulation may result in the calpain and CaMKK2 
activation, contributing to Aβ production and tau phosphorylation. Ryanodine 
receptor dysfunction can also lead to abnormal activation and accumulation of 
PKR kinase in AD brains. PKR kinase is linked to calcium accumulation and PKR 
autophosphorylation can be triggered by Aβ peptides in neuronal cultures in a 
calcium-dependent manner. In turn, PKR activation may lead to Aβ production by 
regulating BACE1 levels and abnormal tau protein phosphorylation by GSK3 activa-
tion. Dantrolene, a RyR inhibitor, may be an AD treatment [9].
2.4 Gamma-Aminobutyric Acid receptor
Gamma-Aminobutyric Acid receptor (GABAR) inhibition is also related to a 
better prognosis in AD. Gamma-Aminobutyric Acid receptor regulates learning, 
memory, and cognition, inhibits Adenylyl Cyclase and the cAMP cascade, as well 
as controls GABA and glutamate release. CGP35348 is a GABA receptor antagonist, 
and the CGP35348 hippocampal concentration is a crucial point for improving 
memory by reducing APP toxicity. Several neurological and psychiatric disorders 
occur with neuronal hyperexcitability in specific regions of the brain or spinal cord, 
partly due to some loss and/or dysfunction of GABAergic inhibitory interneurons 
[10]. Strategies which improve inhibitory neurotransmission in the affected brain 
regions may decrease deficits associated with these disorders. This perception has 
prompted an interest in testing the efficacy of GABAergic interneuron grafting 
in the brain or spinal cord regions which exhibit hyperexcitability, GABAergic 
interneurons scarcity, or impaired inhibitory neurotransmission, using preclinical 
models of neurological and psychiatric disorders [10]. Defective GABAergic neu-
ronal functions can lead to cortical network hyperactivity and aberrant neuronal 
oscillations and thereby generate a detrimental change in memory processes [11]. 
In this context, GABAergic cell therapy may decrease neurological deficits in AD 
preclinical models [10]. Alzheimer patients have low GABA levels in the brain and 
spinal cerebrospinal fluid (SCF), and these changes are more severe in ApoE4 allele 
carriers. ApoE4 is associated with increased brain activity at rest and memory tasks, 
possibly reflecting impaired GABAergic inhibitory control. In addition, GABA 
levels in human SCF change with aging, constituting the strongest AD risk factor. 
Therefore, ApoE4 may at least partially contribute to the AD pathogenesis, causing 
age-dependent impairment in GABAergic interneurons [12].
2.5 Receptor for advanced glycation end products
The relationship between the receptor for advanced glycation end products 
(RAGE) and AD has also recently been established; RAGE is widely expressed and 
regulated in the AD brain. Furthermore, RAGE is involved with the transport of 
beta-amyloid protein through the blood-brain barrier (BBB) to the brain paren-
chyma. Interactions between RAGE and APP result in inflammatory responses and 
oxidative stress, as well as reduce cerebral blood flow. The receptor also inhibits the 
elimination of APP and RAGE ligands such as AGE, HMGB1, and S100β, which are 
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involved in the neurodegenerative disease progression. Additionally, RAGE/AGE 
interactions induce the apoptosis cascade and neuronal inflammation [7]. In addi-
tion, RAGE has been considered as a therapeutic approach in AD; in fact, a RAGE 
antagonist demonstrated a protective effect in an animal model. Chronic oral dos-
ing of PF-04494700 antagonist in transgenic AD mice reduced Aβ levels, improved 
performance in spatial memory testing, and normalized the electrophysiological 
recordings of hippocampal slices. According to the results of the Phase II clinical 
study [13], the RAGE inhibitor has an excellent safety profile and is well-tolerated 
for over 10 weeks in patients with oral AD. These inhibitors block the binding of Aβ 
peptides to the RAGE V domain as well as inhibit the cell stress induced by Aβ in 
cells expressing RAGE in vitro, as well as in the brains of mice [14].
Moreover, a RAGE inhibitor (FPS-ZM1) has no animal toxic activity and easily 
crosses the BBB. In aged mice with AD, FPS-ZM1 can inhibit the RAGE-mediated 
influx of Aβ40 and Aβ42 in the brain. FPS-ZM1 binds exclusively to RAGE in 
the brain, inhibiting Aβ production and suppressing microglia activation and 
neuroinflammatory response. Blocking RAGE actions in the SCF and brain normal-
izes cognitive performance and cerebral blood flow. FPS-ZM1 is a potent RAGE 
blocker, thereby controlling the progression of Aβ-mediated brain disorder [14]. 
Furthermore, metabolic syndrome is a risk factor for cognitive decline in AD, and 
RAGE has been associated with metabolic syndrome, as this receptor directly con-
tributes to an inflammatory process and oxidative stress. Thus, the RAGE inhibition 
is able to reduce cellular toxicity, and therefore, RAGE inhibitors have therapeutic 
potential in retarding AD progression [15].
2.6 Vitamin D receptor
Vitamin D (VD) acts through the vitamin D receptor (VDR), expressed in 
various tissues, including the nervous system. Vitamin D receptor is related to 
memory and cognitive functions. Research has reported a higher prevalence of VD 
deficiency in AD patients and individuals with VD deficiency had twice the risk 
of developing AD compared with individuals with sufficient VD concentrations. 
Several potential mechanisms which link low VD levels to the risk of dementia 
have been identified. First, VDR is expressed throughout the brain, including areas 
involved in memory, such as the hippocampus. The enzyme which synthesizes the 
active form of VD, 1α-hydroxylase, is also produced in various brain areas. Second, 
the VD active form (1,25dihydroxyvitamin D3 or 1,25-D3) regulates neurotrophin 
expression, such as neurotrophin 3, Glial cell-derived neurotrophic factor (GDNF) 
and neural growth factor (NGF). NGF has been implicated in maintaining and 
regulating the normal function of the septohippocampal pathway, which is involved 
in learning and memory. In addition, NGF levels are substantially reduced in 
AD patients and NGF negatively modulates APP protein gene expression, while 
increased APP expression is observed after NGF suppression. Furthermore, VD 
analogs increase APP binding to the NGF promoter, inducing NGF expression. 
Therefore, 1,25-D3 contributes to the development, survival, and function of neural 
cells [16].
Third, VD can stimulate macrophages, which increases amyloid plaque clear-
ance. Fourth, the antioxidant effect of VD may be related to the modulation 
of antioxidant gene expression. Oxidative stress is known to contribute to the 
pathophysiology of neurodegenerative diseases, which leads to impaired cognitive 
and behavioral function. Genetic analyses of the human genome have pointed to 
several genes playing a role in susceptibility to AD, such as genes which are involved 
in inflammation and oxidative stress [7]. Fifth, VD also plays a role in vascular 
protection. Sixth, VD regulates neurotransmitter metabolism in the CNS, such as 
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acetylcholine, dopamine, serotonin, and aminobutyric gamma acid. Finally, VD 
also reduces Aβ-induced cytotoxicity and apoptosis in primary cortical neurons. 
A recent study found that Aβ induction of nitric oxide synthase, part of the AD 
inflammatory process, depends on the VDR pathway disruption. VD supplementa-
tion improves age-related cognitive decline, learning, and memory in older rats. A 
cross-sectional study found that VD deficiency was associated with increased white 
matter volume and reduced gray matter volume. In summary, low VD concentra-
tions may increase the risk of dementia and AD through vascular and neurodegen-
erative mechanisms [16].
2.7 Retinoid X receptor
Vitamin D receptor interacts with the retinoid receptor X (RXR) to perform 
VD actions. Retinoid receptor X activation can stimulate the normal physiological 
processes by which APP is eliminated from the brain. Thus, RXR agonists may be 
useful in treating AD. Two-week treatment with an RXR agonist (bexarotene) 
in an AD animal model resulted in clearance of intraneuronal amyloid deposits. 
Additionally, treatment with bexarotene improved remote memory stabilization 
in fear-conditioned mice and improved olfactory habituation. In addition, bexaro-
tene pretreatment improved neuronal survival in response to glutamate-induced 
excitotoxicity. The bexarotene effects were accompanied by reduced amyloid plaque 
levels, decreased astrogliosis and suppression of inflammatory gene expression. 
Therefore, treatment with RXR agonists can decrease neuron loss, reverse cognitive 
deficits, and improve neural circuit function in aggressive AD models [17]. Retinoid 
receptor X agonists can increase the expression of ApoE, ABCA1, and ABCG1 
by activating RXR heterodimers. On the other hand, these beneficial effects are 
blocked by the RXR antagonist, which can accentuate cellular oxidative stress [18].
Interestingly, RXR decreased expression was identified in the AD mouse model 
and in cells treated with Aβ peptides [19]. However, the action mechanism of 
RXR ligands remains unknown, particularly in the context of human ApoE [20]. 
Retinoids have effects on various physiological and pathological processes in the 
brain. For example, retinoic acid (RA) signaling is widely detected in the adult 
CNS, including the amygdala, cortex, hypothalamus, hippocampus, and other 
brain areas. Retinoids are mainly involved in neural patterns, axon differentiation, 
and cell growth. Retinoids also play a key role in preserving the differentiated state 
of adult neurons. Impaired RA signaling may result in neurodegeneration and 
AD progression. Recent studies have shown severe deficiencies in mouse learn-
ing and memory during RA deprivation, indicating its importance in preserving 
memory. Defective cholinergic neurotransmission is related to cognitive deficits in 
AD. Retinoic acid is also known to increase choline acetyltransferase expression and 
the activity in neuronal cell lines. In addition, retinoids have been shown to inhibit 
the expression of proinflammatory chemokines and cytokines in microglia and 
astrocytes, which are activated in AD [21].
2.8 N-methyl-d-aspartate receptors
N-methyl-d-aspartate receptors (NMDAR) participate in CNS development 
and are involved in synaptic plasticity, which is essential for learning and memory. 
Cognitive symptoms associated with learning and memory deficits have been 
associated with glutaminergic neurotransmission disorders. Excitatory glutamin-
ergic neurotransmission via NMDAR is critical for synaptic plasticity and neuron 
survival. However, excessive neuron stimulation by the glutamate neurotransmit-
ter causes cytotoxicity and results in neuronal damage and death, underlying a 
Neuroprotection - New Approaches and Prospects
6
potential mechanism of neurodegeneration in AD. Therefore, blocking NMDAR 
receptor-mediated glutaminergic neurotransmission can decrease cytotoxicity, 
thereby preventing further damage to neurons and cellular oxidative damage [22]. 
Therefore, NMDAR antagonists have emerged as potential compounds for AD 
patients since the receptor itself has many subunits and its variants have several 
brain functions. For example, conantokine acts as an NMDA receptor antagonist 
and plays an important role in understanding the importance of NMDA receptor 
inhibition in the AD treatment. Moreover, NMDAR activation might be blocked 
by an AD drug, memantine, an NMDAR antagonist which selectively blocks the 
function of extra synaptic NMDARs, but does not affect normal neurotransmission. 
However, memantine (and other current medications used to treat AD) only relieve 
the symptoms and do not alter the disease progression [23].
2.9 Cholesterol receptors
Regarding cholesterol receptors, some specific genotypes have been related 
to a higher or lower risk of dementia and AD. Even genotypes associated with 
AD neuropathology attenuation could be associated with late-onset of dementia. 
Liver nuclear X receptors (LXRs) are the main regulators of cholesterol homeo-
stasis and CNS inflammation. The brain, which contains about 25% of total body 
cholesterol, requires a complex and balanced cholesterol metabolism to maintain 
neuronal function. Deregulation of cholesterol metabolism has been implicated in 
several neurodegenerative diseases, including AD. Due to their anti-inflammatory 
activities, LXRs play a crucial role in CNS function. Although LXR agonists have 
therapeutic potential in neurological diseases, the use of LXR in these patholo-
gies remains problematic. The recent discovery of cholesterol derivatives which 
function as LXR agonists has shown new roles for LXRs in midbrain neurogenesis. 
Elucidating the repertoire of endogenous ligands for LXR will improve the under-
standing of how this receptor regulates CNS lipid metabolism [24].
Nuclear X receptor signaling affects AD development through various path-
ways. Studies indicate that LXR genetic loss in transgenic mice results in increased 
amyloid plaques. Studies also suggest that LXRs activation in mice improves the 
expression of cholesterol efflux-linked genes (ApoE and ABCA-1), induces APP 
processing, and reduces Aß synthesis, with significant improvement in memory. 
Furthermore, LXR agonists have also been shown to inhibit neuroinflammation 
by modulating microglial phagocytosis and repressing COX2, MCP1, and INOS 
expression in glial cells [25]. The T allele of NR1H2 (rs2695121) presents the most 
significant risk for AD among all LXR-β gene polymorphisms. Taken together, these 
findings suggest that brain-penetrable LXR agonists or LXR modulators may be 
useful therapeutic agents for AD treatment and prevention [26].
Additionally, chromosome 12p has been recognized as an AD-associated region. 
This chromosome includes genes for LDL receptor 1 (LRP1) and oxidized low-
density lipoprotein receptor 1 (OLR1). OLR1 is a class E scavenger receptor and is 
a transmembrane glycoprotein. In vitro factors such as oxidized LDL, oxidative 
stress, and inflammatory cytokines, as well as in vivo factors such as diabetes mel-
litus, hyperlipidemia, and hypertension, may induce OLR1 expression. Increased 
oxidized LDL levels induce endothelial cell activation and dysfunction, apoptosis, 
and impaired vessel relaxation, thus contributing to atherosclerosis development 
and progression through OLR1. Epidemiological and clinical literature has reported 
an association between atherosclerosis, vascular risk factors, and AD. Therefore, 
ORL1 variations may lead to low efficiency in the oxidized LDL removal and 
therefore increased Aβ levels, which may result in neuronal death. Indeed, a single 
nucleotide polymorphism in OLR1 located in the 3′ untranslated region of the gene 
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may influence regulatory microRNA binding and OLR1 homeostasis. Several stud-
ies have reported an association between this variant and AD [27].
2.10 Toll-like receptors
Toll-like receptors (TLRs) are innate immune system receptors which are acti-
vated by pathogens (PAMP) or damage-associated molecular patterns (DAMPs). 
Toll-like receptors are associated with neuronal injury in chronic inflammatory 
conditions but also with functional recovery after nerve injury. Amyloid aggregates 
seem to be a type of DAMP and may interact and activate standard recognition 
receptors. Two TLR actions (ligand binding and immune signaling) may have 
beneficial effects on AD pathology. Moreover, microglial activation represents an 
important AD hallmark. Analysis of genetic polymorphisms suggested relation-
ships between TLR polymorphisms and AD risk, further supporting the hypothesis 
that TLRs are involved in AD [28]. In fact, TLR2 is elevated in the hippocampus 
and cortex of AD patients and mice. In this context, it was observed that a TLR2-
binding peptide (WT TIDM) inhibited Aβ-induced microglial activation, reduced 
Aβ load, attenuated neuronal apoptosis, and improved memory and learning in 
mice. However, WT TIDM peptide was not effective in TLR2 knockout mice [29].
Importantly, TLR5 binds to APP with high-affinity, forming complexes which 
block APP toxicity. In turn, APP fibrils modulate the human TLR5 activation via fla-
gellin, but APP cannot activate TLR5 signaling by themselves. Thus, TLR5-related 
biological data suggest this receptor as a potential agent in AD therapy [30]. A new 
TLR9 signaling pathway has recently been associated with the immune-inflam-
matory response, reducing Aβ levels in AD mice. Therefore, TLR9 may represent a 
functional candidate gene for AD [31]. Moreover, TLR4 has also been described in 
the brain and seems to regulate some physiological processes such as neurogenesis. 
In this sense, TLR4 plays an important role during neurodegenerative disorders. 
PRDX6 has been shown to inhibit neural stem cell neurogenesis by down-regulating 
the TLR4 signaling pathway [32]. An early TLR3-mediated signal improves Aβ 
neuronal autophagy, although it increases neuronal apoptosis in the late stage of 
AD. Similarly, TLR7, TLR8, and TLR9 may improve early Aβ microglial uptake, but 
over time, they contribute to neuroinflammation. Therefore, TLRs, in particular 
TLR2 and TLR4, represent suitable targets for therapeutic intervention in AD and 
carefully targeting them may increase Aβ autophagy and phagocytosis, as well as 
reduce inflammatory responses. Several modulators with selective TLR agonist 
or antagonist activity have been developed, and many of them could produce a 
therapeutic benefit in AD patients [33].
2.11 Chemokine receptors
Another molecule involved in AD is the chemokine receptor CX3C1 (CX3CR1), 
which performs IL-1β-dependent cognitive functions. It is known that CX3CR1 
maintains microglial homeostasis and is essential for microglia function in synaptic 
support since it is highly expressed in microglia. In vivo, CX3CR1-GFP knock-in 
mice (in which GFP replaced a CX3CR1 allele) were used to study the role of 
microglia in AD and other brain diseases. Under physiological conditions, decreased 
CX3CR1 function affects cognitive functions in an IL-1β-dependent manner, as 
well as exacerbates LPS-induced inflammation, suggesting that CX3CR1 is essential 
for nerve synapses. In this context, CX3CL1/CX3CR1 axis dysregulation in AD 
may have neuroprotective and neurotoxic effects depending on the model used. It 
is also possible that CX3CR1 is involved in the death of neurons with intracellular 
TAU deposits and the subsequent TAU release [34]. Still, regarding chemokine 
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receptors, CCL2 receptor (CCR2) was also associated with AD since CCR2 promotes 
the recruitment of bone marrow monocytes into the APP deposition sites in the 
parenchyma, where APP phagocytosis occurs. In mice, CCR2 deficiency accelerated 
early AD progression, impairing mononuclear phagocyte accumulation. CCR2−/− 
mice exhibited high APP levels and low CD11b+ cell recruitment in the brain. 
Importantly, these mice had increased mortality in a dose-dependent manner of the 
CCR2 gene. Subsequent studies showed that APP reduction is due to the monocyte 
accumulation in the perivascular spaces and possibly its infiltration into the brain 
parenchyma. These findings were corroborated by the fact that CCR2 deficiency 
worsened memory and increased soluble APP levels in mice [34].
2.12 Glucocorticoid receptors
The main AD risk factor is aging, but there is growing evidence that chronic 
stress or stress-related disorders may increase the chance of developing AD. Thus, 
depressive disorder may be a risk factor for AD [35]. Stress promotes AD progres-
sion on neurons and glial cells, supporting an important pro-inflammatory role 
of glucocorticoid (GC) in the CNS [36]. Glucocorticoids act via two receptors: 
mineralocorticoid and glucocorticoid receptors (GR) and can participate in APP 
generation and APP activity in the brain. There is a cross-talk between APP and 
GRs in hippocampal excitatory synapses, which may contribute to abnormal brain 
activity during the AD pathogenesis. Both AD patients and AD mice have dysregu-
lated hypothalamic-pituitary-adrenal (HPA) axis, marked by hypercortisolemia 
early in the AD pathology. Thus, in early AD, while APP levels slowly increase in the 
brain, GR activity is probably abnormally high [37]. Moreover, GRs hyperactiva-
tion induces brain changes similar to AD changes. In the brain, GCs are regulators 
of dendritic spine renewal and microglia activity, two strongly altered phenomena 
in AD. Although well established that GCs initiate the brain neuroinflammatory 
response, it is not known whether GRs modulate dendritic spine plasticity and 
microglial activity in AD [36].
Several strategies aiming GR has been tested to counteract HPA axis dysregula-
tion and GC overproduction. Given the GR ubiquitous expression, antagonists have 
many side effects, limiting the GR therapeutic potential. However, a new class of 
selective molecules has been developed, acting as GR modulators. They selectively 
reduce GR-dependent pathogenic processes while retaining the beneficial aspects of 
GR signaling. Indeed, these “selective GR modulators” induce receptor conforma-
tions that allow the activation of only a subset of downstream signaling pathways, 
explaining their ability to combine agonistic and antagonistic properties. Therefore, 
targeting GR with selective modulators, alone or in association with current 
strategies, is attractive to develop new strategies aiming disorders associated with 
HPA axis dysregulation [35]. Dexamethasone, a GR agonist, was able to reduce 
the dendritic spine density, induced the microglia proliferation, and activated the 
microglia in the mouse hippocampus. Besides, in vitro microglial cells were acti-
vated by dexamethasone. In contrast, treatment with mifepristone, a GRs antago-
nist, strongly increased dendritic column density, decreased microglia density, and 
improved mice behavioral performance [36].
2.13 G-protein-coupled receptor 40
There are a large number of polyunsaturated fatty acids in the nervous system, 
such as docosahexaenoic acid (DHA), an omega 3 carboxylic acid. The DHA binds 
to G-protein-coupled receptor 40 (GPR40) and exerts protective effects on the 
nervous system. For example, GPR40 can increase synaptic plasticity, neuronal 
9Alzheimer’s Disease Neuroprotection: Associated Receptors
DOI: http://dx.doi.org/10.5772/intechopen.91918
activity, and inhibits neuronal apoptosis. In this context, GPR40 was considered a 
possible target in dementia [38]. The receptor is expressed in several brain areas, 
including the hippocampus, which is involved in learning and spatial memory. 
However, few studies are investigating the functional role of GPR40 in the brain 
[39]. One study evaluated the GPR40 functional role in the AD mouse model. 
Groups treated with GPR40 significantly improved cognitive performance and 
GPR40 agonist-treated groups improved learning and memory skills in various 
tests. Besides, GPR40 activation caused CREB phosphorylation and increased 
neurotrophic factors levels, including brain-derived neurotrophic factor (BDNF), 
nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4) in 
hippocampal neurons. These results suggest that GPR40 can be a therapeutic can-
didate for neurogenesis and neuroprotection in AD treatment and prevention [39] 
since GPR40 agonists can promote adult neurogenesis, inhibit neuronal apoptosis, 
and play a vital role in protecting nerves and decreasing brain damage [38].
2.14 Triggered receptor expressed on myeloid cells 2
The triggered receptor expressed in myeloid cells 2 (TREM2) is a soluble protein 
carried by macrophages through ventricles and choroid plexus, entering the brain 
parenchyma through radial glial cells. TREM2 is important for innate immunity, but 
it is also essential for neuroplasticity and myelination. During later stages of life, 
the TREM2 absence can accelerate aging processes, neuronal cell loss and reduce 
microglial activity, leading to neuroinflammation. Inflammation plays an important 
role in neurodegenerative diseases and TREM2 can be important to immunomodu-
lation and neuroprotection [40]. As a member of the immunoglobulin superfamily, 
TREM2 can suppress inflammatory responses, mediates phagocytic pathways, is 
involved with neuronal survival and neurogenesis, as well as contributes to CNS 
neuroimmune homeostasis. Changes in TREM2 are involved in AD-related neuro-
pathology, including Aβ deposition, tau hyperphosphorylation, neuroinflamma-
tion, and neuronal and synaptic losses in AD animal models. However, the precise 
underlying mechanisms about TREM2 have not yet been fully characterized [41]. 
Besides, TREM2 might be related to microglial activation, promoting the associa-
tion of microglial cells with APP plaques. Therefore, microglia can decrease APP 
plaque growth, limiting APP toxicity. On the other hand, this phagocytotic capacity 
is impaired by TREM2 deficiency. Moreover, different mutations in TREM2 are 
associated with AD [42, 43]. Interestingly, recent findings also suggested that the 
association between TREM2 variants and the AD risk varies according to different 
ethnicities and populations [41].
2.15 5-Hydroxytryptamine 6 receptor
The serotoninergic neurotransmitter system has been implicated in AD patho-
genesis. The 5-hydroxytryptamine 6 receptor (5HTR6) is expressed in brain areas 
involved with cognitive processes and has been investigated as a possible thera-
peutic target in AD symptomatology. Besides, 5HTR6 may be added to currently 
approved “Food and Drug Administration” therapies: cholinesterase inhibitors 
and NMDA receptor antagonists since 5HTR6 controls the pyramidal neurons’ 
migration during corticogenesis. In addition, 5HTR6 is a TOR signaling activa-
tor and seems to regulate GABAergic, glutamatergic, and cholinergic activity. 
Therefore, 5HTR6 is involved in cognition, anxiety, memory, affective state, among 
others [44]. Several kinds of research have been conducted with selective 5HTR6 
antagonists. These antagonists act by modulating the glutamate and GABA levels, 
consequently increasing dopamine, ACh, and norepinephrine concentrations in 
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the brain, all compromised in AD. Besides, 5HTR6 agonists have also been shown 
to have pro-cognitive effects. Partial or inverse agonists may produce promising 
cognitive effects [44, 45]. Moreover, 5HTR6 gene variants can be a genetic risk 
factor for late-onset AD and 5HTR6 polymorphisms are possibly involved with AD 
susceptibility, such as the C267T polymorphism [44]. However, there are relatively 
few genetic studies investigating the association between AD and gene variants 
involved in the serotonergic system.
2.16 Cannabinoid receptors
Evidence regarding the involvement of the endocannabinoid system (ECS) in 
the AD pathogenesis raised questions about the development of new therapeutic 
approaches for AD based on endocannabinoid regulation. The endocannabinoid 
system is composed of receptors, endogenous ligands, and enzymes, which are 
involved in AD pathogenesis [46]. Endocannabinoid system-directed drugs can 
exert beneficial effects on mood, as well as modulate neuroinflammation, synaptic 
plasticity, neurotoxicity, apoptosis, cell proliferation, cell differentiation, and 
oxidative stress [47, 48]. Moreover, cannabis tetrahydrocannabinol (THC) induces 
neurogenesis, removes Aβ peptides, and decreases neurofibrillary tangles. The 
hippocampus and microglia, key actors in dementia pathophysiology, express 
1 and 2 cannabinoid receptors, respectively [49]. Type 2 cannabinoid receptor 
(CNR2) is overexpressed in activated microglia in different areas of the nervous 
system. Activated CNR2 has the potential to disrupt the AD process and treat the 
symptoms, reducing neurodegeneration, neuroinflammation, and improving 
spatial memory [50]. The role of the type 1 cannabinoid receptor (CNR1) is unclear. 
However, CNR1 can up-regulate anti-apoptotic proteins in rats [49].
2.17 Peroxisome proliferator-activated γ receptor
Peroxisome proliferator-activated γ receptor (PPARγ) regulates the transcrip-
tion of several genes involved in inflammation, immune response, insulin sensitiv-
ity, and lipid metabolism. The pathways governed by PPARγ overlap the biological 
pathways implicated in AD pathogenesis according to various pieces of evidence. 
Besides, PPARγ regulates the expression of seven AD-associated genes, including 
ApoE, ABCA1, and ABCG1. Increasing ApoE lipid levels facilitate soluble Aβ deg-
radation. Studies using AD animal models have suggested that PPARγ exerts direct 
and indirect effects on APP protein metabolism [51]. Peroxisome proliferator-
activated γ receptor is up-regulated in AD due to existing neuroinflammation and 
PPARγ agonists can be used in AD and shows anti-inflammatory effects, as well as 
improve learning and memory. Thus, PPARγ might be a significant new therapeutic 
target in AD treatment [52]. In addition, emerging evidence suggests that PPARγ 
effectively regulates microglia activation under physiological and pathological 
conditions, facilitating Aβ microglial phagocytosis [53]. In addition, PPARγ poly-
morphisms have been studied in AD; however, the results are controversial and 
inconclusive [54].
2.18 NOD-like receptor pyrin domain-containing-3
The NOD-like receptor pyrin domain-containing-3 (NLRP3) is the best 
known member of the NLR family. Importantly, APP can activate the NLRP3 
inflammasome and increase NLRP3, caspase1, and IL1-β genes expression [55]. 
In microglia, NLRP3 activation is essential for interleukin-1β (IL1-β) maturation 
and subsequent inflammatory events. Besides, NLRP3 is possibly involved in AD 
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pathogenesis through oxidative stress [56]. One study showed that NLRP3 knock-
out mice were largely protected from spatial memory loss and other AD-associated 
sequelae, showing reduced caspase-1 and IL1-β activation, as well as increased 
Aβ clearance. Microglial activation by Aβ can initiate innate immune responses in 
CNS via NLRP3, even before the Aβ deposition. These results show an important 
role of the NLRP3 axis in the AD pathogenesis and suggest that NLRP3 inflam-
masome inhibition might be a new therapeutic intervention for the disease [57]. 
Non-steroidal anti-inflammatory drugs can inhibit NLRP3 inflammasome via 
reversible blockade of volume-regulated anionic channels in the plasma mem-
brane, inhibiting cognitive impairment in AD mice models [58]. The loss of NLRP3 
inflammasome function also reduced tau hyperphosphorylation and aggregation 
(involved in AD pathogenesis) by regulating tau kinases and phosphatases. Tau, in 
turn, activated the NLRP3 inflammasome. The intracerebral injection containing 
Aβ induced tau pathology in an NLRP3-dependent manner. Therefore, these data 
suggest an important role of NLRP3, microglia, and inflammasome activation in 
AD tauopathies [59]. Finally, virgin coconut oil improved hippocampal health, 
memory, and learning in AD mice models by inhibiting NLRP3 and reducing 
oxidative stress [55].
3. Conclusion
Nuclear receptors family and G-protein-coupled receptors are probably the 
receptors families most involved with AD (Table 1). Additionally, the cerebral 
cortex is the main area where most of the receptors involved in AD express 
themselves. The cerebral cortex’s physical area, its complexity, and its involve-
ment with several relevant functions in AD probably justify this fact. Despite the 
small size of the hippocampus, this region is significantly affected in AD. While 
the cerebral cortex is mainly involved in decision making, subjective thinking, 
consequences of action assessment, perception, and attention, the hippocampus is 
mainly related to memory. As a key component of cortico-hippocampal networks, 
the perirenal cortex plays an important role in memory processes, especially 
familiarity-based recognition memory. Therefore, disrupted functional connec-
tivity of this cortical region as a result of early neurodegeneration may contribute 
to altered brain rhythms and cognitive failures observed in the early clinical phase 
of AD patients [11].
Although few receptors involved with AD are expressed in the hypothalamus 
and amygdala (when compared to the expression in the cortex, hippocampus, pons, 
medulla, and basal ganglia), it is known that AD is closely associated with changes 
in mood and motivation. However, these associations depend on the AD stage. 
Most of the receptors involved with AD are expressed in more than one nervous 
system area, showing the involvement of several brain regions in AD. Additionally, 
microglia is one of the main cell types in which AD-associated receptors express 
themselves, highlighting the relevance of microglia in AD, especially in the removal 
of toxic peptides. Additionally, AD-associated receptors are involved with several 
metabolic pathways, which may be directly or indirectly related to the disease. The 
APP elimination or the blockage of pathways related to the APP synthesis is the 
main function performed by the receptors involved with AD (Table 1, Figure 1). 
Besides, many receptors are directly involved with cognitive, memory, and/or learn-
ing functions and many receptors are associated with more than one AD-related 
function (Table 1, Figure 1). Finally, AD-associated receptors are also related to 
nervous system plasticity, including neuronal and microglial survival, nervous 
system development (positive plasticity), and neuronal death (negative plasticity). 
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Receptor/family Main expression 
area in human 
CNS






Interacts with APP protein and exert positive 
effects on memory and attention [1, 2].
Estrogen receptors (ER)
Nuclear receptor family
Basal ganglia and 
hippocampus
Increases neural plasticity and neurogenesis, 
affecting cognitive functions and the brain 
regenerative potential. May play beneficial effects 
in reducing the brain inflammatory process [4–6].
Ryanodine receptor 3 (RyR3)
Calcium channels
Basal ganglia Plays negative effects related to synaptic 
transmission and synaptic plasticity. Associated 





Cerebral cortex Regulates learning, memory, cognitive function, 
controls the glutamate release, and reduces APP 
toxicity [10–12].
Receptor for advanced 




Cerebellum Contributes to neuronal death and inflammation 
and is involved with the APP transport, oxidative 
stress, and cerebral blood flow [14, 15].




Interacts with SMAD3, regulating APP 
transcription through TGFβ signaling. Suppress 
APP gene promoter activity [16].
Retinoid X receptor (RXR)
Nuclear receptor family
Cerebral cortex Stimulates physiological mechanisms of APP 







Participates in CNS development and is involved 
in synaptic plasticity, essential for learning and 
memory [22, 23].
Liver X receptor β (LXR)
Nuclear receptor family
Cerebral cortex Regulates the cholesterol homeostasis and 
inflammation in CNS. May play roles in 





Pons and medulla Mediates the increase in ApoE expression induced 
by APP protein [27].
Oxidized low-density 
lipoprotein receptor 1 
(OLR1)
Lipoprotein receptor family
Midbrain Mediates the uptake and internalization of low-
density oxidized lipoprotein (oxLDL), which may 
be involved in AD [27].
Toll-like receptor 4 (TLR4)
Toll-like receptor family
Hippocampus Induces CREB signaling, which regulates 
neuron survival, neuronal gene expression, and 
neurogenesis in the adult subventricular zone  
[28, 32, 33].
Toll-like receptor 5 (TLR5)
Toll-like receptor family
Thalamus Binds to APP oligomers and fibrils, forming 
complexes that block APP toxicity [28, 30, 31].
C-C chemokine receptor 
type 2 (CCR2)
Chemokine receptor family
Pons and medulla Promotes monocyte recruitment to APP 
deposition sites, where these cells can phagocyte 
APP proteins [34].





Maintains microglial function in synaptic support 
and performs IL-1β dependent cognitive  
functions [34].
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This suggests that these receptors participate in several long-term changes in the 
nervous system (long-term plasticity) [60].
Finally, most of the receptors involved in AD (67%) are associated with ben-
eficial effects on the disease. These receptors include nuclear receptors, such as 
VDR, membrane receptors, such as TLR5, and cytoplasmic receptors, such as 
GABAR. Most of the AD-associated receptors are found in the membrane of nerve 
cells (61%). Among the neuroprotective receptors, we can highlight the vitamin 
D receptor, responsible for vitamin D actions. Vitamin D is increasingly recog-
nized as a substance involved in neuronal survival, taking part in psychiatric and 
Receptor/family Main expression 
area in human 
CNS





Cerebellum Participates in the generation and activity of APP 





Spinal cord Promotes neurogenesis, inhibits neuronal 
apoptosis, and plays a role in protecting nerves and 
decreasing brain damage [38, 39].
Triggered receptor expressed 
on myeloid cells 2 (TREM-2)
Immunoglobulins 
superfamily
Midbrain Participates in microglial survival, inflammatory 






Basal ganglia Controls the pyramidal neurons migration during 
corticogenesis, activates TOR signaling, and 
regulates the GABAergic, glutamatergic, and 
cholinergic activity. Involved in cognition, anxiety, 





Cerebral cortex Disrupt the AD process, reduce symptoms, 
neurodegeneration, neuroinflammation, and 
improve spatial memory [47–50].
Peroxisome proliferator-
activated γ receptor (PPARγ)
Nuclear receptor family
Amygdala Participates in pathways involved with lipid 
metabolism and immune response implicated 
in AD etiology. PPARγ acts as a transcriptional 
regulator of several genes involved in AD 
pathogenesis [51–53].




Pons and medulla The NLRP3 activation leads to IL-1β and IL-18 
production that play a role in the inflammatory 




Cerebral cortex Inhibits enzymes involved in AD, such as 
acetylcholinesterase, 5-lipoxygenase, and 
monoamine oxidase. Protects neurons against 
oxidative stress, contributing to neuronal tissues 
repair [64].






Role in hippocampal neurons degeneration. 
APP is able to increase intracellular calcium by 
opening calcium-permeable cationic channels in 
hippocampal neurons [65].
Table 1. 
Alzheimer’s disease associated receptors.
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neurodegenerative diseases such as AD. The participation of vitamin D in neuronal 
survival may be related to its role in inhibiting the cellular oxidative stress and APP 
synthesis. Therefore, supplementation with vitamin D can help in the current AD 
treatment [61]. A beneficial role in inflammation, played by some receptors acting 
on inflammatory pathways, such as TLRs, has also been shown to be beneficial in 
the AD treatment [62]. More and more new treatments are being researched for 
AD, but unfortunately, the improvements have not been significant. What has 
been sought are combinations of treatments, which can result in some side effects 
in the elderly patient. Besides, current treatments are only symptomatic, that is, 
they do not modify the AD stage. These are cholinesterase inhibitors, used in all AD 
stages as they result in some beneficial effects on cognition and behavior. However, 
therapies affecting the AD stage are still under development. Therefore, efficient 
research must be conducted in this direction, instead of alleviating only the symp-
toms. Immunotherapy, for example, can be a viable option soon [63].
Figure 1. 
Proteins associated with AD. Proteins related to AD are shown according to their protective (a) or pathological 
(b) effects in AD. The receptors located in the green boxes are associated with neuroprotective effects on 
AD. Receptors located in red boxes are associated with AD pathophysiology. Proteins are shown according 
to their location in the cell (nucleus, membrane, intracellular or extracellular). Arrows/triangles represent 
activation, induction or increase. Inverted bars/triangles represent inhibition, deficit or decrease. Protein 
associated to AD protection are related to proteins involved in AD pathophysiological process. Two triangles 
represent overactivation. Elements in the figure are not showed in real scale. ROS, reactive oxygen.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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